In 2026, the industry is pivoting toward "Genomic-Linked SaMD" that suggests chemotherapy dosages with molecular precision. This year, a radical new class of software is being used to analyze a p...
The 2026 Peripheral Neuropathy Market is moving rapidly toward "Genomic-Based" treatment. This year, "Pharmacogenomic" testing is being used to determine why some patients respond to antidepressa...
